Could this Healthcare Stock really climb 1,285.06% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- November 2, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [EX-CIA Advisor: Israel war will speed up Saudi Attack on America?]( A former Pentagon insider says Saudi Arabia – where most of the 9/11 terrorists were from… Is about to unleash the ultimate “weapon of mass destruction” on the US. [>>Click here to see his uncensored warning.]( --------------------------------------------------------------- [Seelos Therapeutics]( Symbol: [SEEL]( Recent Price: $0.18 Average Analyst Price Target: $2.50 (1,258.70%) Market Cap: $27.33M Last Year's EPS: -$0.12 Consensus EPS Forecast: -$0.09 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Yatin Suneja, analyst at Guggenheim, reiterates coverage on [Seelos Therapeutics (SEEL)]( in the Healthcare sector with a Hold rating (1 month ago). [TipRanks.com]( also reports that [Seelos Therapeutics]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.50 . The target pricing ranges from a high forecast of $4 down to a low forecast of $1. [Seelos Therapeutics (SEEL)](’s last closing price was $0.18 which would put the average price target at 1258.70% upside. Here are 3rd party ratings for [SEEL](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [AI to Disrupt Energy Market (Huge Potential Gains!)]( orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… It makes them all look like small fries… In fact, just one year of this untapped resource in the USA alone provides 5X as much power as the largest oil field on Earth… And this resource is about to be unleashed on the world like never before with the help of one tiny Silicon Valley company…[Click here for all the details…]( --------------------------------------------------------------- [Icahn Enterprises]( Symbol: [IEP]( Recent Price: $16.36 Average Analyst Price Target: $27.00 (65.04%) Market Cap: $6.89B Last Year's EPS: -$0.75 Consensus EPS Forecast: $0.25 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Daniel Fannon, analyst at Jefferies, reiterates coverage on [Icahn Enterprises (IEP)]( in the Industrials sector with a Buy rating and a price target of $27 (2 months ago). [TipRanks.com]( also reports that [Icahn Enterprises]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $27.00 . The target pricing ranges from a high forecast of $27 down to a low forecast of $27. [Icahn Enterprises (IEP)](’s last closing price was $16.36 which would put the average price target at 65.04% upside. Here are 3rd party ratings for [IEP](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 35% (160 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- [Privia Health Group]( Symbol: [PRVA]( Recent Price: $20.42 Average Analyst Price Target: $30.10 (65.28%) Market Cap: $2.43B Last Year's EPS: $0.06 Consensus EPS Forecast: $0.06 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Jeffrey Garro, analyst at Stephens, reiterates coverage on [Privia Health Group (PRVA)]( in the Healthcare sector with a Buy rating and a price target of $27 (3 days ago). [TipRanks.com]( also reports that [Privia Health Group]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $30.10 . The target pricing ranges from a high forecast of $36 down to a low forecast of $26. [Privia Health Group (PRVA)](’s last closing price was $20.42 which would put the average price target at 65.28% upside. Here are 3rd party ratings for [PRVA](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 25% (61 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [GPT-4 vs. X.AI: The Race of the New AI Giants]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- [Brookfield Business Partners]( Symbol: [BBU]( Recent Price: $13.14 Average Analyst Price Target: $27.00 (97.91%) Market Cap: $978.97M Last Year's EPS: $0.34 Consensus EPS Forecast: $1.05 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Andrew Kuske, analyst at Credit Suisse, reiterates coverage on [Brookfield Business Partners (BBU)]( in the Real Estate sector with a Buy rating and a price target of $26 (2 months ago). [TipRanks.com]( also reports that [Brookfield Business Partners]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $27.00 . The target pricing ranges from a high forecast of $35 down to a low forecast of $18. [Brookfield Business Partners (BBU)](’s last closing price was $13.14 which would put the average price target at 97.91% upside. Here are 3rd party ratings for [BBU](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 35% (160 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- [AdvanSix]( Symbol: [ASIX]( Recent Price: $27.23 Average Analyst Price Target: $47.00 (72.60%) Market Cap: $761.15M Last Year's EPS: $1.22 Consensus EPS Forecast: $1.07 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Charles Neivert, analyst at Piper Sandler, reiterates coverage on [AdvanSix (ASIX)]( in the Basic Materials sector with a Buy rating and a price target of $40 (3 weeks ago). [TipRanks.com]( also reports that [AdvanSix]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $47.00 . The target pricing ranges from a high forecast of $57 down to a low forecast of $40. [AdvanSix (ASIX)](’s last closing price was $27.23 which would put the average price target at 72.60% upside. Here are 3rd party ratings for [ASIX](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Bottom 11% (218 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Gold is about to SOAR – here’s what you need to do]( is lining up perfectly for a historic gold bull run. One gold research firm says they’ve found the best way to get in, for less than $5. --------------------------------------------------------------- [AlloVir]( Symbol: [ALVR]( Recent Price: $1.54 Average Analyst Price Target: $19.50 (1,285.06%) Market Cap: $164.50M Last Year's EPS: -$0.44 Consensus EPS Forecast: -$0.45 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Jason Zemansky, analyst at Bank of America Securities, reiterates coverage on [AlloVir (ALVR)]( in the Healthcare sector with a Buy rating and a price target of $17 (2 months ago). [TipRanks.com]( also reports that [AlloVir]( currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.50 . The target pricing ranges from a high forecast of $27 down to a low forecast of $15. [AlloVir (ALVR)](’s last closing price was $1.54 which would put the average price target at 1,285.06% upside. Here are 3rd party ratings for [ALVR](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 34% (84 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- [Arcutis Biotherapeutics]( Symbol: [ARQT]( Recent Price: $2.26 Average Analyst Price Target: $25.20 (1,296.90%) Market Cap: $216.55M Last Year's EPS: -$1.31 Consensus EPS Forecast: -$1.22 Expected Earnings Date: Nov 03 2023 Recent Analyst Action: Uy Ear, analyst at Mizuho Securities, reiterates coverage on [Arcutis Biotherapeutics (ARQT)]( in the Healthcare sector with a Hold rating and a price target of $4 (1 week ago). [TipRanks.com]( also reports that [Arcutis Biotherapeutics]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $25.20 . The target pricing ranges from a high forecast of $6 down to a low forecast of $22. [Arcutis Biotherapeutics (ARQT)](’s last closing price was $2.26 which would put the average price target at 1,296.90% upside. Here are 3rd party ratings for [ARQT](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 30% (73 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Tech Insider: "ChatGPT's IPO - is this the final clue?"]( posted a strange legal promise to early investors on their website -- And what it says is truly shocking if you read between the lines. It’s why venture capitalist Luke Lango now believes an IPO announcement could happen at any moment. [Click here to see how to prepare.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. [If you are not a human, click here.]( MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software